Currentsierra health and lifePolicy 2026T0051DD

Chelation Therapy

This policy governs coverage for chelation therapy for UnitedHealthcare Commercial and Individual Exchange benefit plans, specifying medically necessary indications (heavy metal overload) and conditions considered unproven or not medically necessary.

Policy Summary

Payersierra health and life

PolicyChelation Therapy

Policy CodePolicy 2026T0051DD

Change TypeTemplate update — no material changes

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain validated diagnostic testing and document confirmed heavy metal overload before requesting prior authorization for chelation therapy.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

5+primary chelating agents or codes listed

1708participants in TACT trial (EDTA chelation)

435participants in pediatric DFP vs DFX trial

0high-quality evidence for non-overload diseases

FDA listhigh-risk groups for dental amalgam

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Chelation Therapy

inv-01: Medically Necessary Indications — Covered when ALL of the following are met

Covered when ALL of the following are met

Heavy metal overload indication: Chelation therapy is proven and medically necessary for diagnosed heavy metal toxicity and overload conditions (e.g., iron, copper, lead, aluminum).

Documented diagnosis and appropriate diagnostic workup required; diagnostic testing should consider history, appropriate methods, and specific reference values.

inv-02: Not Medically Necessary / Unproven Indications — Not covered for the following

Not covered for the following

Non-overload or unproven uses: Chelation therapy for chronic, progressive diseases associated with non-overload conditions (including but not limited to cardiovascular disease, rheumatoid arthritis, cancer, diabetes, Alzheimer’s disease, Parkinson’s disease) is unproven and not medically necessary due to insufficient evidence of efficacy.

Dental amalgam-related mercury: Chelation therapy for treating mercury 'toxicity' from dental amalgam fillings is unproven and not medically necessary; dental amalgams have not been shown to cause harm except in rare allergy cases.

inv-03: Iron overload — medically necessary criteria for transfusion-dependent hemoglobinopathies

Covered when ALL of the following are met for iron-overload due to transfusion-dependent hemoglobinopathies

Iron-overload chelation (transfusion-dependent hemoglobinopathies): 1) Documented transfusion-dependent hemoglobinopathy with biochemical or imaging evidence of iron overload (e.g., serum ferritin and cardiac MRI T2*); 2) Treatment plan specifies an appropriate oral iron chelator (examples include deferiprone or deferasirox) with dosing and monitoring; 3) Clinical rationale references randomized trial evidence supporting efficacy and safety in pediatric transfusion-dependent populations.

Supported by a multicenter randomized non-inferiority trial (DFP vs DFX) showing DFP non-inferior over ~12 months; document transfusion dependence and iron-overload biomarkers.

inv-04: Non-overload indications — investigational / not medically necessary (list of non-overload conditions)

Not medically necessary / investigational for the following non-overload conditions due to insufficient or conflicting evidence

Non-overload conditions: Use of chelation therapy (oral or parenteral EDTA-based solutions, DMSA, clioquinol/PBT compounds, dexrazoxane except where specifically indicated) for conditions including but not limited to: cardiovascular disease/ASCVD/PAD (including routine post-MI use), prevention of recurrent MI, Alzheimer’s disease, autism spectrum disorder, Parkinson’s disease, chronic fatigue syndrome, rheumatoid arthritis, multiple sclerosis, cancer, diabetes as a primary indication, mercury toxicity from dental amalgam, and other chronic/progressive diseases where metal overload is not established — is investigational or not medically necessary due to insufficient, conflicting, or low-quality evidence.

Multiple systematic reviews and RCTs are inconsistent or do not demonstrate clinically meaningful benefit; trials such as TACT/TACT2 and Cochrane reviews have not established routine benefit for CVD and other non-overload indications.

inv-05: Medically necessary indications (additional set) — Covered when ALL of the following are met

Covered when ALL of the following are met

Primary coverage criteria: Chelation therapy using FDA-approved agents is covered only for FDA-approved indications such as documented metal poisoning or iron overload, diagnosed with validated testing in appropriate biological samples.

Documentation must include validated diagnostic testing and clinical justification; professional society guidance (ACMT, AAFP) supports chelation only for documented metal intoxication.

inv-06: Not medically necessary / discouraged uses — Not covered or not recommended when ANY of the following apply

Not covered or not recommended when ANY of the following apply

Excluded indications: Use of chelation therapy for autism, cardiovascular disease prevention or treatment (including EDTA to improve angina/exercise tolerance or prevent MI), neurodegenerative conditions, stable ischemic heart disease, or other unproven/non-overload indications is not medically necessary or is discouraged.

Multiple society statements and guidelines (ACMT, AAFP, AAP, ACP, AHA, Canadian Cardiovascular Society, NICE) advise against these uses and note potential harms of inappropriate chelation.

Chelation therapy is excluded for use in chronic, progressive diseases when there is no objective evidence of metal overload. Specifically, chelation to treat non-overload conditions (for example, cardiovascular disease, diabetes, neurodegenerative diseases, autoimmune disorders, cancer, or other chronic progressive illnesses) is considered unproven and not medically necessary. Similarly, chelation to treat alleged mercury 'toxicity' from dental amalgam fillings is excluded because dental amalgams have not been shown to cause harm except in rare cases of allergy; therefore chelation for this indication is not medically necessary.

Use of chelation for autism spectrum disorder is specifically excluded. A Cochrane review found no clinical-trial evidence that pharmaceutical chelation improves ASD symptoms, and prior reports of serious adverse events (including hypocalcemia, renal impairment, and death) mean that the risks outweigh any unproven benefits. More broadly, well-designed peer-reviewed studies do not support chelation for autism or for numerous other non-overload conditions; such uses are considered not medically necessary and are at risk for denial.

Edetate disodium (EDTA)-based chelation is not approved by the FDA for prevention or treatment of cardiovascular disease. Major professional societies and clinical guidelines state that EDTA chelation is not recommended to prevent MI, reduce cardiovascular risk, or improve symptoms of stable ischemic heart disease; therefore EDTA should not be used for routine CVD management.

Restating exclusions: chelation therapy for chronic progressive non-overload diseases and for treatment of purported mercury toxicity from dental amalgam fillings is considered unproven and not medically necessary. Dental amalgam has not been demonstrated to cause clinically significant mercury toxicity in routine exposures, aside from rare allergy, and therefore chelation is not an appropriate therapy for these claims.

EDTA-based chelation has been evaluated recently in a large 2024 randomized, double-masked, placebo-controlled multicenter trial of patients with prior myocardial infarction and diabetes. That trial (n=959 randomized; median follow-up ~48 months) showed no meaningful difference in the primary composite cardiovascular endpoint between chelation and placebo despite lowering blood lead levels. Systematic reviews and prior trials likewise show insufficient evidence of clinical benefit for routine post-MI use; consequently, routine EDTA chelation for secondary prevention after MI is not medically necessary.

In summary, chelation is an evidence-based treatment only for documented metal intoxication or objective metal overload. There is no high-quality evidence to support chelation as an effective therapy for autism, cardiovascular disease, or neurodegenerative conditions; professional toxicology and cardiology organizations conclude these are unsupported uses. Therefore chelation for these conditions is considered not medically necessary.

Coding and Relevant Codes

Referenced Drug HCPCS CodesHCPCS

J0470	Injection, dimercaprol, per 100 mg.
J0600	Injection, edetate calcium disodium, up to 1,000 mg.
J0895	Injection, deferoxamine mesylate, 500 mg.
J3490	Unclassified drugs.
J3520	Edetate disodium, per 150 mg.
J8499	Prescription drug, oral, nonchemotherapeutic, NOS

Referenced Procedure Codesmixed

M0300	IV chelation therapy (chemical endarterectomy).
S9355	Home infusion therapy, chelation therapy; administrative services, professional pharmacy services, care coordination, and all necessary supplies and equipment (drugs and nursing visits coded separately), per diem

FDA informational referencesmixed

No codes listed

inv-16: Dental amalgam contribution to TBHg — key study result

Dental amalgam contribution to total blood mercury (TBHg)6.47%

Study population4,484 pregnant women (single UK region)

Comparator exposureSeafood accounted for 8.75% of TBHg in same cohort

Provider Requirements, Prior Authorization, and Documentation

Prior Authorization

Prior Authorization Required for Iron Overload Chelation

Prior authorization is required for chelation therapy when used to treat iron overload (e.g., transfusion-related iron overload) and other documented metal overload conditions. Provide documentation of the specific diagnosed overload (e.g., transfusion-dependent hemoglobinopathy), the chelating agent requested, dose and route, planned treatment duration, and supporting evidence such as serum ferritin trends, liver iron concentration (LIC) by MRI (R2*/Ferriscan) or cardiac T2* MRI when applicable. Authorization decisions will consider trial-supported agents (for iron overload) such as deferiprone (DFP), deferasirox (DFX), and deferoxamine (DFO) and relevant clinical trial evidence.

Affected codes (examples): J0895 (deferoxamine mesylate), J0470 (dimercaprol), J0600 (edetate calcium disodium), J3520 (edetate disodium) — see code list for full billing guidance.
Include clinical rationale and prior therapies tried or contraindications to alternatives when applicable.
For iron overload: include baseline and recent serum ferritin, LIC (MRI R2*/Ferriscan) and cardiac T2* if cardiac involvement suspected.

Definitions and Key Terms

inv-31: Definition — Chelation therapy

DefinitionAdministration of molecules that bind and promote excretion of specific metal toxins; agent, route, and dosing vary by toxin and clinical context.

Common agentsExamples include deferoxamine, deferiprone, deferasirox, EDTA, DMSA (agent choice depends on metal and indication).

Routes and deliveryOral and parenteral (IV) administration depending on agent, toxicity level, and clinical indication.

inv-32: Definition — Non-overload conditions

DefinitionClinical conditions without demonstrated acute or chronic heavy metal toxicity in which chelation is hypothesized to provide benefit (e.g., by reducing oxidative damage); evidence for benefit is lacking or incomplete.

Mechanistic rationale

Background

Chelation therapy is an established and appropriate treatment when an individual has an objectively diagnosed heavy metal overload (for example, iron, copper, lead, or aluminum) confirmed by validated testing and clinical assessment. For these overload indications, chelating agents have proven clinical benefit when used according to accepted diagnostic and monitoring standards.

Policy Summary

Payersierra health and life

PolicyChelation Therapy

Policy CodePolicy 2026T0051DD

Change TypeTemplate update — no material changes

Effective DateJan 1, 2026

Next Review Date

Key ActionObtain validated diagnostic testing and document confirmed heavy metal overload before requesting prior authorization for chelation therapy.

SourceLink

On This Page

Denial Risk

Denial Triggers — Non‑Overload Indications

Chelation therapy is not medically necessary for non-overload chronic conditions (including, but not limited to, cardiovascular disease, atherosclerosis, diabetes, cancer, Alzheimer’s disease, autism spectrum disorder, Parkinson’s disease, rheumatoid arthritis, chronic fatigue syndrome, multiple sclerosis, and other listed conditions). Requests for chelation to treat these non-overload indications should be denied.

Denial triggers include: requests for chelation to prevent or treat CVD/CAD, improve angina or exercise tolerance, treat chronic neurodegenerative or psychiatric conditions, or to remove alleged metabolic toxins where no documented metal overload exists.
Chelation for removal of mercury from dental amalgam fillings is considered unproven and not medically necessary.
Requests lacking validated diagnostic testing confirming metal intoxication or overload should be denied.

Denial Risk

Do Not Use Chelation (e.g., EDTA) for Cardiovascular Prevention/Treatment

Chelation (including EDTA) should not be used for prevention or treatment of cardiovascular disease or to improve cardiovascular symptoms outside of documented metal intoxication. Major professional societies state chelation is not recommended for CVD and EDTA is not FDA‑approved for preventing or treating CVD.

Do not authorize EDTA chelation for primary prevention of MI, to reduce cardiovascular risk, to improve symptoms of chronic stable angina, or to improve exercise tolerance absent documented metal overload.
For patients with CVD who have documented metal overload, authorization requires validated testing and specific documentation of overload and clinical rationale.

Documentation Required

Diagnostic Workup — Required Elements

Diagnostic workup and documentation must support the indication for chelation. The workup should include a relevant exposure and medical history, selection of appropriate, validated testing methods, and use of proper biological samples and reference values per professional guidance.

Document patient history including exposure source, symptoms, transfusion history, and any prior chelation or mitigating treatments.
Specify the tests performed (e.g., serum ferritin, transferrin saturation, LIC by MRI R2*/Ferriscan, cardiac T2*, blood/urine lead levels) and provide numeric results with laboratory reference ranges and method used.
Validated testing in appropriate biological samples is required for authorization; non-validated or anecdotal testing is insufficient.

Documentation Required

Diagnostic Documentation for Approved Indications

For approved indications (documented metal intoxication or iron overload), documentation must include validated diagnostic testing and objective measures of overload or toxicity. Provide baseline and recent objective measures to justify initiation or continuation of therapy.

For iron overload: include transfusion history, baseline and follow-up serum ferritin, liver iron concentration by MRI (R2*/Ferriscan), and cardiac T2* MRI when indicated.
For other metal poisonings (e.g., lead, copper, aluminum, mercury): include specific validated blood or urine measurements using appropriate specimen types and laboratory methodology, clinical signs of toxicity, and source of exposure.
Include treatment plan: agent, dose, route, frequency, anticipated duration, monitoring plan for efficacy and toxicity, and plans to manage known drug-specific adverse effects (e.g., neutropenia with deferiprone).

Denial Risk

Do Not Approve Chelation Absent Validated Diagnostic Confirmation

Providers must not submit authorization requests for chelation without evidence of documented metal intoxication diagnosed using validated tests. Inappropriate chelation exposes patients to significant risks (eg, hypocalcemia, renal injury, liver enzyme elevations, hematologic toxicity) and may result in claim denials and/or repayment.

If validated testing does not confirm overload or intoxication, deny the request and document the reason for denial in the member record.
Counsel patients seeking chelation for dental amalgam removal that chelation for this purpose is unproven and not medically necessary; avoid chelation solely to remove mercury from amalgam fillings except when validated mercury toxicity is documented and meets criteria.

Hypothesized mechanism: removal of metal ions may reduce oxidative damage from hydroxyl radicals, but this mechanism is not fully understood or validated clinically.

Examples of proposed usesCardiovascular disease, rheumatoid arthritis, cancer, diabetes, autism spectrum disorder, neurodegenerative diseases, and mercury from dental amalgam.

inv-33: Definition — EDTA (edetate disodium)

DefinitionEdetate disodium (EDTA) is an IV, multi-component chelation solution used to bind divalent metals (e.g., lead) for removal.

Trial contextEvaluated in large multicenter randomized trials including the TACT and a 2024 double-masked, placebo-controlled multicenter trial of EDTA-based chelation in post-MI patients with diabetes (88 sites, 959 participants).

Primary outcomes noted2024 trial showed reduction in blood lead levels but no difference in primary cardiovascular event rates between chelation and placebo groups.

inv-34: Definition — DFP (deferiprone)

DefinitionDeferiprone (DFP) is an oral iron chelator used to remove excess iron in transfusion-dependent hemoglobinopathies and investigated for brain iron reduction in Parkinson’s disease.

Pediatric trial contextMaggio et al. (2020) multicenter, randomized, non-inferiority trial comparing oral DFP versus deferasirox (DFX) in pediatric transfusion-dependent hemoglobinopathies (435 participants); DFP was non-inferior over ~12 months.

PD trial contextSmall randomized trial (Martin-Bastida et al., 2017) of DFP in early Parkinson’s (22 participants) showed tolerability and some regional brain iron reductions but was underpowered for clinical outcomes.

inv-35: Definition — High-risk groups for dental amalgam exposure (FDA advisory)

FDA high-risk groups (recommend avoid dental amalgam when possible)Pregnant women and their developing fetuses

Additional high-risk groupsWomen planning pregnancy; nursing women and newborns/infants; children (especially <6 years).

Clinical vulnerability categoriesPeople with pre-existing neurological disease (e.g., MS, Alzheimer’s, Parkinson’s), impaired kidney function, or known hypersensitivity to mercury/DA components.

inv-36: Dental amalgam contribution to blood mercury — cohort study result

Cohort resultDental amalgam fillings accounted for approximately 6.47% of total blood mercury (TBHg) in a cohort of 4,484 pregnant women.

Study limitationsDA exposure measures relied on retrospective questionnaire (recall bias) and timing of blood draw relative to dental work was unknown.

Comparative exposureIn the same cohort, seafood consumption accounted for 8.75% of TBHg, for perspective on exposure sources.